Quanterix (NASDAQ: QTRX) files Akoya acquisition pro forma data

Rhea-AI Filing Summary

Quanterix Corporation filed an amendment to a current report to provide additional financial details related to its acquisition of Akoya Biosciences, Inc. The acquisition of Akoya was completed on July 8, 2025 under an Amended and Restated Agreement and Plan of Merger dated April 28, 2025 among Quanterix, a merger subsidiary, and Akoya.

This amendment adds unaudited pro forma condensed combined financial statements for Quanterix and Akoya for the year ended December 31, 2024 and as of and for the six months ended June 30, 2025, which are included as Exhibit 99.1. The historical financial statements of Akoya were previously filed in a post-effective amendment to Quanterix’s Form S-4 registration statement and are incorporated by reference rather than repeated here.

Quanterix Corpfalse000150327400015032742025-07-082025-07-08

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

______________________________________

FORM 8-K/A

______________________________________

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 8, 2025

_________________________________________________

QUANTERIX CORPORATION

(Exact name of registrant as specified in its charter)

_________________________________________________

Delaware			001-38319			20-8957988
(State or other jurisdiction of incorporation)			(Commission File Number)			(IRS Employer Identification No.)

900 Middlesex Turnpike
Billerica, MA			01821
(Address of principal executive offices)			(Zip Code)

(617) 301-9400

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class:

Trading symbol(s):

Name of each exchange on which registered:

Common Stock, $0.001 par value per share

QTRX

The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging Growth Company o

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Explanatory Note

On July 8, 2025, Quanterix Corporation, a Delaware corporation (“Quanterix”), filed a Current Report on Form 8-K (the “Original Report”) to report the completion of its previously announced acquisition of Akoya Biosciences, Inc. a Delaware corporation (“Akoya”), on that same date. The acquisition was consummated pursuant to the terms of that certain Amended and Restated Agreement and Plan of Merger dated as of April 28, 2025, by and among Quanterix, Wellfleet Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Quanterix, and Akoya.

This Amendment No. 1 to Current Report on Form 8-K amends the Original Report to include the pro forma financial information required under Items 9.01(b) and excluded from the Original Report in reliance on Item 9.01.

Item 9.01    Financial Statements and Exhibits.

(a)Financial Statements of Business Acquired.

The historical financial statements of Akoya were previously reported in Post Effective Amendment No. 2 to the Registration Statement on Form S-4 filed by Quanterix on June 4, 2025 (File No. 333-284932) and are omitted in reliance on General Instruction B.3 to Form 8-K.

(b)Unaudited Pro Forma Financial Information

The unaudited pro forma condensed combined financial statements for the year ended December 31, 2024 and as of and for the six months ended June 30, 2025 giving effect to the acquisition of Akoya are filed as Exhibit 99.1 to this Amendment No. 1 to the Current Report on Form 8-K and incorporated in this Item 9.01 by reference.

(d)Exhibits

Exhibit No.						Description
99.1						Unaudited pro forma condensed combined financial statements of Quanterix Corporation and Akoya Biosciences, Inc. for the year ended December 31, 2024 and as of and for the six months ended June 30, 2025.
104						Cover Page Interactive Data File (embedded within the inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Current Report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: September 23, 2025			QUANTERIX CORPORATION
			By:			/s/ Vandana Sriram
			Name:			Vandana Sriram
			Title:			Chief Financial Officer

FAQ

What did Quanterix (QTRX) change in this amended report?

Quanterix filed an amendment to a current report to add unaudited pro forma condensed combined financial statements for Quanterix and Akoya Biosciences, Inc., providing combined financial information after the acquisition.

When did Quanterix complete the acquisition of Akoya Biosciences?

The acquisition of Akoya Biosciences, Inc. by Quanterix was completed on July 8, 2025 under an Amended and Restated Agreement and Plan of Merger dated April 28, 2025.

Which periods do the new pro forma financial statements for Quanterix and Akoya cover?

The unaudited pro forma condensed combined financial statements cover the year ended December 31, 2024 and as of and for the six months ended June 30, 2025.

Where can investors find Akoya’s historical financial statements in relation to Quanterix’s acquisition?

Akoya’s historical financial statements were previously included in Post Effective Amendment No. 2 to Quanterix’s Registration Statement on Form S-4 (File No. 333-284932) filed on June 4, 2025 and are incorporated by reference.

What exhibit contains the new pro forma information in Quanterix’s amended filing?

Exhibit 99.1 contains the unaudited pro forma condensed combined financial statements of Quanterix Corporation and Akoya Biosciences, Inc. for the specified periods.

Who signed the amended report for Quanterix Corporation?

The amended report was signed on behalf of Quanterix Corporation by Vandana Sriram, who is the Chief Financial Officer.